Hematology and oncology franchise
Celgene’s (CELG) hematology and oncology franchise consists of Revlimid, Pomalyst, Abraxane, Idhifa, Vidaza, Istodax, and Thalomid. Revlimid’s revenues grew from $3.9 billion in the first half of 2017 to $4.7 billion in the first half of 2018, which reflects ~19.6% growth YoY (year-over-year).
Revlimid is used to treat multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma. In July, Celgene announced that its AUGMENT trial of the Revlimid and rituximab combination therapy for treating individuals with relapsed/refractory follicular and marginal zone lymphoma met its primary endpoint. In the phase 3 AUGMENT trial, the Revlimid and rituximab combination therapy demonstrated a statistically significant improvement in progression-free survival, which was the trial’s primary endpoint compared to rituximab and a placebo combination therapy.
Celgene will discuss the results with regulatory authorities. The company plans to file a worldwide regulatory filing for the label expansion of Revlimid during the first quarter of 2019.
Pomalyst and Thalomid’s revenue trends
Pomalyst’s net revenues grew from $755.0 million in the first half of 2017 to $960.0 million in the first half of 2018, which reflects ~27.2% growth YoY. In the first half of 2018, Pomalyst witnessed ~40.3% growth.
Polamyst’s net revenues grew from $391.0 million in the first half of 2017 to $507.0 million in the first half of 2018, which reflects ~29.7% growth YoY. The US market mainly pushed Pomalyst’s growth in the second quarter with ~41.5% growth YoY.
Thalomid’s revenues fell 15.7% YoY in the first half of 2018 to net revenues of $59.0 million from $70.0 million in the first half of 2017.
In the multiple myeloma market, Celgene leads the immunomodulatory agent class of drugs with Revlimid, Pomalyst, and Thalomid. Some other important drugs for multiple myeloma include Takeda Pharmaceutical’s (TKPYY) Velcade, Amgen’s (AMGN) Kyprolis, and Novartis’ (NVS) Farydak. Notably, Amgen’s Kyprolis reported revenues of $263.0 million in the second quarter.